Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Development stage company NanoViricides has started preliminary animal trials of the company's HIV therapeutic candidates at a BioSafety Level 3 Laboratory facility in Boston, Massachusetts.
Subscribe to our email newsletter
The initial results are expected before the end of May, 2008. These animal studies will be conducted by Krishna Menon, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics.
Eugene Seymour, CEO of NanoViricides, said: “The purpose of this initial study is twofold: To assess therapeutic efficacy and to determine the appropriate dosages of drug that should be used in the later animal study. If initial performance goals are met, it will be a critical first step in validating the company’s HivCide-I as a potential treatment for HIV/AIDS.”